Novartis Takes Aim At Systemic Mastocytosis With Midostaurin
Executive Summary
Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.
You may also be interested in...
Three CHMP Negative Opinions ‒ But Who Got A Boon?
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Novartis Oncology Strategy: Focus On The Microenvironment
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.